Last reviewed · How we verify
NCT05316428
A Study of the Hemodynamic Interactions of TPN171H Tablets & Alcohol in Healthy Male Subjects
Phase 1 trial testing TPN171H tablet plus alcohol in Alcohol in 19 participants. Completed in 6 April 2022.
2 April 2022
Quick facts
| Lead sponsor | Vigonvita Life Sciences |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 19 |
| Start date | 24 February 2022 |
| Primary completion | 2 April 2022 |
| Estimated completion | 6 April 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- TPN171H tablet plus alcohol — full drug profile →
- alcohol — full drug profile →
- TPN171H tablet
Conditions studied
- Alcohol — all drugs for Alcohol →
- Phosphodiesterase Inhibitor — all drugs for Phosphodiesterase Inhibitor →
- Erectile Dysfunction — all drugs for Erectile Dysfunction →
Sponsor
Vigonvita Life Sciences — full company profile →
Who can join
Adults 21 to 45, male only, with Alcohol or Phosphodiesterase Inhibitor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is primarily to evaluate the effects of taking TPN171H tablets with alcohol on blood pressure, pulse,and pharmacokinetic in Chinese healthy male subjects.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Hemodynamic and Pharmacokinetic Interactions of TPN171 with Alcohol in Healthy Male Subjects.
Cheng J, Qian H, Wang Y, Liang L, et al · · 2025 · PMID 39960841 · DOI 10.1111/cts.70165
Verify or expand the search:
- PubMed search for NCT05316428
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alcohol
Currently open trials in the same condition.
- NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
- NCT06994338 — Tirzepatide for Alcohol Use Disorder · Phase 2 · recruiting
Other Vigonvita Life Sciences trials
Trials by the same sponsor.
- NCT07507838 — Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV913 Capsules · EARLY_PHASE1 · not yet recruiting
- NCT07302269 — Study of the Safety, Tolerability, Pharmacokinetics of VV261 Tablets in Chinese Healthy Volunteers · Phase 1 · recruiting
- NCT06749236 — A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension · Phase 1 · completed
- NCT06828887 — Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD · Phase 2 · recruiting
- NCT06504290 — Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119 · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05316428 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vigonvita Life Sciences
- Last refreshed: 23 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05316428.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing